University: University of Glasgow
Sector(s): Life Sciences, Chemical, Healthcare & Pharmaceuticals
The AS/AGU rat is a model of locomotor dysfunction with progressive disruption and degeneration of the nigrostriatal dopaminergic system.
The AS/AGU rat provides an exciting new model for the evaluation of new treatments for Parkinson’s disease. The AS/AGU rat is the only model in which degenerative events take place over a sufficiently long period of time to mimic human conditions and to allow the exploration of mechanisms of cell loss and the role of neuro-protectants and further evaluation of novel therapies It is characterised by wide gait, hind limb rigidity, whole body tremor, difficulties in initiating movement and a tendency to fall over when moving quickly. These animals display a Parkinsonian-like movement disorder which can be reversed by L-DOPA treatment.
- The model shows analogy with human impairment since it is progressive and age related
- Background research shows L-DOPA replacement can ameliorate movement disorders
- The identity of the causal mutant gene is known and patented. This genetic knowledge will facilitate the molecular characterisation of the cellular site of the dysfunction.
- It is the only model in which degenerative events take place over a sufficiently long period of time to mimic human conditions and to allow the exploration of mechanisms of cell loss and the role of neuro-protectants and novel therapies.
- The rats breed very well.
Excellent and reliable model for the pre-clinical trial and evaluation of potential new treatments for Parkinson’s disease.
This technology is available as an Easy Access licence deal to companies and individuals giving:Physical access to the rat model Non-exclusive access to the content of the patents on the model (now lapsed) Non-exclusive access to the background IP and know-how of the model Access to the inventors